On April 16, 2026 Revvity, Inc. reported its latest innovations in cancer research at the AACR (Free AACR Whitepaper) Annual Meeting 2026, to be held in San Diego, April 17-22. The Company’s comprehensive suite of research use only (RUO) oncology solutions are designed to elevate preclinical and translational research workflows, helping scientists accelerate discoveries that drive the future of cancer science.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The full scope of Revvity’s integrated oncology solutions and reagents that will be on display are designed to support the entire cancer research workflow from sample preparation and assay development, to advanced imaging, detection, and data analysis. By combining innovative technologies with AI-driven insights, Revvity helps researchers generate high-quality, reproducible data and uncover deeper biological insights faster.
"Our focus is on empowering researchers with connected, end-to-end solutions that remove complexity and accelerate progress," said Kevin Quick, vice president, platforms at Revvity. "At AACR (Free AACR Whitepaper), we’ll demonstrate how our technologies are helping advance cancer research and ultimately contribute to improved patient outcomes."
Attendees will experience several of Revvity’s latest innovations, including:
Opera Phenix OptIQ high-content screening system for advanced 3D and live-cell imaging
Living Image Synergy AI software for multimodal in vivo imaging data analysis
EnVision Nexus One multimode plate reader for high-sensitivity detection and performance
AssayMate automated workstation for simplified, accessible sample preparation
Dharmacon ON-TARGETplus 2.0 siRNA for potent on-target mRNA knockdown with siRNA designed against the modern genome
Next-generation reagents and assay solutions, such as ATPlite and Spark PLUS UV395, designed to enhance workflow consistency and data quality
Together, these solutions reflect Revvity’s strategy to deliver integrated technologies that connect workflows, reduce variability, and enable more confident decision-making in cancer research, including advanced cellular imaging, AI-enabled in vivo analysis, high-performance detection, automation, and genomics tools.
By bringing together instrumentation, reagents, software, and services, Revvity supports researchers at every stage of the scientific journey, helping overcome complex research challenges, increase productivity, and translate discoveries into meaningful impact.
(Press release, Revvity, APR 16, 2026, View Source [SID1234664448])